好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of REM Sleep Behavior Disorder on Orthostatic Hypotension in Multiple System Atrophy
Movement Disorders
P3 - Poster Session 3 (5:30 PM-6:30 PM)
10-017

 To investigate whether polysomnogram (PSG)-proven rapid eye movement sleep behavior disorder (RBD) is associated with the severity of orthostatic hypotension (OH) in patients with multiple system atrophy (MSA).

RBD is a non-motor symptom in patients with α-synucleinopathy, such as Parkinson’s disease (PD) and MSA. In PD patients, RBD is associated with the clinical manifestations of both motor symptoms and other non-motor symptoms, such as OH and cognition correlating with poor prognosis. However, little is known about whether RBD affects the clinical manifestation in MSA.

Thirty MSA patients who underwent PSG, including 16 patients with MSA-P and 14 patients with MSA-C, according to the second consensus statement of the diagnosis of MSA, were retrospectively evaluated in this study. Assessment of OH and cognitive function were evaluated by the change of blood pressure within the first 3 minutes after standing and the Mini-Mental State Examination, respectively. 

Seventy-three percent of overall MSA patients were complicated with PSG-proven RBD. The baseline demographics data regarding gender, age at the onset of MSA and age at the evaluation did not show any difference between these groups. The marked reduction in systolic blood pressure after standing (24.1±14.3 vs 0.8±13.4, p=0.009) and diastolic blood pressure (10.1±13.4 vs -3.3±4.6, p=0.075) were observed in MSA-P patients with RBD. In contrast, RBD did not affect the degree of orthostatic hypotension in MSA-C patients. The cognition was not related to the presence or absence of RBD in both MSA-P and MSA-C patients.

Our study revealed that MSA-P patients complicated with RBD show severe OH,  though not in MSA-C patients, implying that the propagation of abnormal α-synuclein in the lesions associated with OH is different between MSA-P and MSA-C, as well as the difference of primary lesion in each subtype, such as basal ganglia or cerebellum.

Authors/Disclosures
Yuji Saitoh, MD, FAAN (Tokyo Metropolitan Neurological Hospital)
PRESENTER
Dr. Saitoh has received stock or an ownership interest from Meiji Holdings Co. Ltd.. Dr. Saitoh has received stock or an ownership interest from Daiichi Sankyo Co. Ltd.. Dr. Saitoh has received stock or an ownership interest from Japan Tobacco Inc.. Dr. Saitoh has received stock or an ownership interest from Otsuka Holdings Co., Ltd.. Dr. Saitoh has received stock or an ownership interest from Fujifilm Holdings Corporation. Dr. Saitoh has received stock or an ownership interest from Johnson & Johnson. Dr. Saitoh has received stock or an ownership interest from 3M Company. The institution of Dr. Saitoh has received research support from Japan Agency for Medical Research and Development (AMED). Dr. Saitoh has received publishing royalties from a publication relating to health care. Dr. Saitoh has received publishing royalties from a publication relating to health care. Dr. Saitoh has received publishing royalties from a publication relating to health care.
No disclosure on file
No disclosure on file
Yuji Takahashi, MD, PhD (National Center of Neurology and Psychiatry) The institution of Dr. Takahashi has received research support from Nihon Medi-Physics Co. Limit.. The institution of Dr. Takahashi has received research support from Takeda Pharmaceutical Company Limited.